The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

A 43-year-old woman presented with 6 months of recurrent bilateral eye pain and redness alongside spontaneous urticaria.She ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

The move combines Epsilogen’s clinical focus on immunoglobulin E (IgE) antibodies with TigaTx’s work on immunoglobulin A (IgA), creating what the companies ... are based on the immunoglobulin G (IgG) ...

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.

Looking ahead, Epsilogen sees the deal as giving it the option to “mix and match IgE, IgA and IgG functionality into a single antibody molecule.” “Such hybrid antibodies have the potential ...

Data from a Phase I trial found it to be safe and well tolerated with early signs of clinical activity EPS 401 (formerly TIGA-001), an anti-EGFR IgA antibody with IND-enabling studies underway ...

Highlights The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen's assets and expertise in IgE to create the world's leading pan-isotype cancer antibody ...

This process is fundamental to the generation of a vast array of antibodies with different specificities ... through point mutations and recombination (29). Unlike mammalian immunoglobulins, which are ...